definiens: means [ * * * ] and [ * * * ] and means any one of them ;, or means ( for the purposes of Clauses 13.2.1, 13.2.2, 14.4 and paragraph 1.8 of Part B Schedule 9,paragraph 1.7 of Part C Schedule 9 and paragraph 1.7 of Part D Schedule 9 ) in the case of a product or a therapy that ( i ) such product ortherapy would, were it not for the applicable licence granted and subsisting hereunder, infringe the applicable Patent Rights so licensedhereunder ; or ( ii ) in the case of the Assigned Patents such product or therapy would, were it not for the assignment to [COMPANY] ( or subsequentassignment or licence grant to an Assignee Entity ) of such Assigned Patent, infringe the applicable Patent Rights so assigned ; means Cancer Research UK ( registered as a company limited by guarantee in England and Wales under number 4325234 ) andregistered charity ( number 1089464 in England and Wales and registered in Scotland under number SC041666 and in the Isle of Man undernumber 1103 ) ; means Cancer Research Technology Limited, with company number 01626049 ( ), CRUK, Leukaemia and LymphomaResearch ( registered as a company limited by guarantee in England and Wales under number 738089 and registered charity number 216032 inEngland and Wales and registered in Scotland under number SC037529 ) ( ) and Kay Kendall Leukaemia Fund ( a registered charity inEngland and Wales with number 290772 ) ( ) ; has the meaning set out in Clause 23.1.1 ; has the meaning set out in Clause 11.1.1(ii ) ; has the meaning set out in Clause 24.4 ; or means those countries that are : ( a ) eligible for support from [ * * * ] ; and ( b ) to the extent notincluded in ( a ), deﬁned as at the Second Amendment Date by the [ * * * ], as such deﬁnitions may be amended from time to time by the WorldBank : has the meaning set out in Clause 29.6 ; has the meaning set out in Clause 20.1 ; has the meaning in Clause 5.2 ; has the meaning set out in Clause 19.2 ; means all uses and applications without restriction ; has the meaning set out in Clause 2.2.12 ; means any product or therapy within the Epitope Tag Field : ( i ) which, were it not for the licence granted hereunder orthe assignment to [COMPANY] ( or subsequent assignment or licence grant to an Assignee Entity ) of the Epitope Tag Patent Rights, would infringe theEpitope Tag Patent Rights ; and/or ( ii ) the manufacture of which product or therapy were it not for the licence granted hereunder or theassignment to [COMPANY] ( or subsequent assignment or licence grant to an Assignee Entity ) of the Epitope Tag Patent Rights, would infringe theEpitope Tag Patent Rights ; and/or ( iii ) where the manufacture of any materials used in connection with the manufacture of such product ortherapy, were it not for the licence granted hereunder or the assignment to [COMPANY] ( or subsequent assignment or licence grant to an AssigneeEntity ) of the Epitope Tag Patent Rights, would infringe the Epitope Tag Patent Rights ( including without limitation the manufacture of the viralvector ultimately used for the manufacture of such product or therapy ) ; means the program of research deﬁned in Schedule 1 under the title Epitope Tag Program as conducted prior to theAmendment Date ; means excluding Manufacturing Know - How, ( i ) those patent applications listed in Schedule 2 under the title EpitopeTag Patents and all Patent Rights derived therefrom ( ) ; ( ii ) the Know - How described in Schedule 2 under the titleEpitope Tag Know - How ; and ( iii ) the materials listed in Schedule 2 under the title Epitope Tag Materials together with all IP in the same ; has the meaning set out in Clause 4.9 ; and means to make, have made, import, export, use, sell or oﬀer for sale, including to research, experiment, develop, commercialise, obtain and maintain Regulatory Approvals, manufacture, to have manufactured, hold or keep ( whether for disposal or otherwise),have used, export, transport, distribute, promote, market or have sold or otherwise dispose of, and shall mean the act ofExploiting ; has the meaning set out in Clause 7.1 ; 6CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [ * * * ], HAS BEEN OMITTED BECAUSE IT IS NOTMATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED